Panacea Biotec (BOM:531349) Construction In Progress: ₹1,000 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:531349 Panacea Biotec Ltd BOM:531349
54 GF Score
Price ₹538.20
GF Value ₹359.92
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Panacea Biotec Construction In Progress?

Panacea Biotec BOM:531349 -0.69% 54 Construction In Progress is ₹1,000 Mil as of Mar. 2026. GuruFocus rates BOM:531349 with a GF Score™ of 54/100 and a GF Value™ of ₹359.92 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Panacea Biotec's quarterly construction in progress declined from Sep. 2025 (₹1,098 Mil) to Dec. 2025 (₹0 Mil) but then increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹1,000 Mil).

Panacea Biotec's annual construction in progress increased from Mar. 2024 (₹763 Mil) to Mar. 2025 (₹974 Mil) and increased from Mar. 2025 (₹974 Mil) to Mar. 2026 (₹1,000 Mil).

Panacea Biotec Construction In Progress Historical Data

* Premium members only.

The historical data trend for Panacea Biotec's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Panacea Biotec Construction In Progress Chart

Panacea Biotec Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 70.79 350.10 762.91 974.13 999.70

Panacea Biotec Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 974.13 0.00 1,098.30 0.00 999.70
BOM:531349
54GF Score
Panacea Biotec Ltd BOM:531349
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Panacea Biotec Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of ₹1,000 Mil mean?
Panacea Biotec (BOM:531349) has a Construction In Progress of ₹1,000 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Panacea Biotec and its competitors.
Is Panacea Biotec's Construction In Progress too high?
Panacea Biotec's current Construction In Progress is ₹1,000 Mil. Overall, Panacea Biotec has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Panacea Biotec's Construction In Progress compare to VRTX and REGN?
Panacea Biotec's Construction In Progress of ₹1,000 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Biotechnology company?
A good Construction In Progress depends on the Biotechnology industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Panacea Biotec and its competitors. Panacea Biotec's current Construction In Progress is ₹1,000 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Panacea Biotec stock overvalued right now?
Based on GuruFocus' analysis, Panacea Biotec (BOM:531349) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹359.92, compared to a current price of ₹538.20 — trading 49.5% above its estimated fair value. The current Construction In Progress is ₹1,000 Mil. Panacea Biotec's overall GF Score™ is 54/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Panacea Biotec (BOM:531349), the current Construction In Progress is ₹1,000 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Panacea Biotec (BOM:531349) Overvalued in 2026?

Based on GuruFocus' analysis, Panacea Biotec stock appears to be overvalued. The current stock price of ₹538.20 is trading 49.5% above its estimated GF Value™ of ₹359.92. GuruFocus considers Panacea Biotec to be Significantly Overvalued.

Key valuation signals for BOM:531349:

  • Construction In Progress: ₹1,000 Mil
  • GF Value™: ₹359.92 vs. price of ₹538.20 (49.5% above fair value)
  • GF Score™: 54/100 with 3 warning signs

No single metric tells the full story. See the BOM:531349 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Panacea Biotec Business Description

Other Exchanges PANACEABIO:India
Address Mathura Road, B-1 Extension/G-3, Mohan Co-operative Industrial Estate, New Delhi, IND, 110044
Panacea Biotec Ltd is a Biotechnology company. It is engaged in the business of research, development, manufacturing, and marketing of branded pharmaceutical formulations, vaccines, and biopharmaceuticals. The company's operating segments include Vaccines, and Formulations. It generates maximum revenue from the Vaccines segment. The company product portfolio includes prescription products in niche therapeutic areas such as diabetes and cardiovascular management, oncology, nephrology and transplant management, osteoporosis management, gastro-intestinal care, pain management products, and pediatric immunization. The group has a business presence in India and Outside India.
54GF Score

Get the complete analysis for BOM:531349

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹538.20
Price
₹359.92
GF Value